PMID- 17126659
OWN - NLM
STAT- MEDLINE
DCOM- 20070216
LR  - 20151119
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 11
DP  - 2006 Dec 1
TI  - Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical 
      course in patients with hypertrophic cardiomyopathy.
PG  - 1504-6
AB  - This study was designed to assess the value of plasma N-terminal pro-B-type 
      natriuretic peptide (NT-pro-BNP) levels in predicting clinical courses in 80 
      patients with hypertrophic cardiomyopathy. Patients were followed for a mean of 
      571 +/- 294 days for clinical end points, defined as a composite of 
      cardiovascular death and hospitalization for worsening heart failure symptoms. 
      NT-pro-BNP plasma level (hazard ratio 1.6, 95% confidence interval 1.10 to 2.55, 
      p = 0.015) and New York Heart Association (NYHA) functional class (hazard ratio 
      3.7, 95% confidence interval 1.17 to 12.09, p = 0.025) were the independent 
      variables associated with increased risk for experiencing clinical end points. 
      NT-pro-BNP plasma level > or =1,500 pg/ml detected patients with clinical end 
      points with sensitivity, specificity, and accuracy of 83%, 81%, and 81%, 
      respectively. The hypertrophic cardiomyopathy population was stratified into 
      low-, medium-, and high-risk subgroups using 2 simple variables, NYHA functional 
      class and NT-pro-BNP. Patients in lower NYHA classes and with NT-pro-BNP levels 
      <1,500 pg/ml were significantly free of clinical end points. In conclusion, for 
      patients with hypertrophic cardiomyopathy, plasma levels of NT-pro-BNP seem a 
      reliable parameter to identify those at risk for clinical deterioration at 
      long-term follow-up in conjunction with symptomatic status.
FAU - Mutlu, Bulent
AU  - Mutlu B
AD  - Department of Cardiology, Kosuyolu Heart and Research Hospital, Istanbul, Turkey.
FAU - Bayrak, Fatih
AU  - Bayrak F
FAU - Kahveci, Gokhan
AU  - Kahveci G
FAU - Degertekin, Muzaffer
AU  - Degertekin M
FAU - Eroglu, Elif
AU  - Eroglu E
FAU - Basaran, Yelda
AU  - Basaran Y
LA  - eng
PT  - Journal Article
DEP - 20061012
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Hypertrophic/*diagnosis/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Prognosis
MH  - Sensitivity and Specificity
EDAT- 2006/11/28 09:00
MHDA- 2007/02/17 09:00
CRDT- 2006/11/28 09:00
PHST- 2006/03/29 00:00 [received]
PHST- 2006/06/20 00:00 [revised]
PHST- 2006/06/20 00:00 [accepted]
PHST- 2006/11/28 09:00 [pubmed]
PHST- 2007/02/17 09:00 [medline]
PHST- 2006/11/28 09:00 [entrez]
AID - S0002-9149(06)01641-9 [pii]
AID - 10.1016/j.amjcard.2006.06.053 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Dec 1;98(11):1504-6. doi: 10.1016/j.amjcard.2006.06.053. Epub 
      2006 Oct 12.